incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
== Arrest, trial, and conviction == In July 2020, Mays was arrested and charged with the murders of eight individuals. The charges were later reduced to seven second-degree murders and one count of intent to commit murder involving the death of the 92-year-old United States Navy veteran Russell R. Posey Sr., who died two weeks after he had been injected with insulin. Prosecutors stated that there were approximately twenty suspicious deaths while Mays worked at the hospital, but charges were brought only for the cases that were believed to have sufficient evidence. On July 14, 2020, Mays pleaded guilty in the United States District Court for the Northern District of West Virginia in Clarksburg to seven counts of second-degree murder and one count of attempted murder. By pleading guilty to all of the charges, Mays waived the right to have the case presented to a grand jury. Mays wept openly in court and admitted that she had murdered the patients. Mays offered no motive but claimed to be taking medication for post-traumatic stress disorder (PTSD). She was held in custody at the West Virginia Regional Jail and Correctional Facility until her sentencing. An interview with Mays after her guilty plea was included in a report, released after the sentencing by the Department of Veterans Affairs' Office of Inspector General, that detailed deficiencies at the hospital.
Division of analytical chemistry and laboratory of bio-electrochemical biosensor research function in this department. The division conducts research in the area of methods of electrochemical analysis using chemically modified electrodes and biosensors. The head of the department is Professor Gennady A. Evtyugin, doctor of Science in chemistry. The Department conducts research in the following fields:
In intrinsic termination, self-complementary sequences within the RNA transcript cause it to double back and form base pairs with itself, creating an RNA stem-loop or hairpin structure. This structure is critical for the release of both the transcript and polymerase at the end of transcription. In living cells, the key components are the stable stem-loop itself, as well as the sequence of 6–8 uracil residues that follow it. The stem usually consists of 8–9 mostly guanine and cytosine (G–C) base pairs, and the loop consists of 4–8 residues. It is thought that the stem portion of the structure is essential for transcription termination, while the loop is not. This is suggested by the fact that termination can be achieved in non-native structures that do not include the loop. The stem portion of the hairpin is usually rich in G–C base pairs. G–C base pairs have significant base-stacking interactions, and can form three hydrogen bonds with each other, which makes them very thermodynamically favorable. Conversely, while the uracil-rich sequence that follows the hairpin is not always necessary for termination, it is hypothesized that the uracil-rich sequence aids in intrinsic termination because the U–A bond is not as strong as G–C bonds. This inherent instability acts to kinetically favor the dissociation of the RNA transcript.
This proved that in aqueous solution, nobelium is most stable in the divalent state when strong oxidizers are absent. Later experimentation in 1974 showed that nobelium eluted with the alkaline earth metals, between Ca2+ and Sr2+. Nobelium is the only known f-block element for which the +2 state is the most common and stable one in aqueous solution. This occurs because of the large energy gap between the 5f and 6d orbitals at the end of the actinide series. It is expected that the relativistic stabilization of the 7s subshell greatly destabilizes nobelium dihydride, NoH2, and relativistic stabilisation of the 7p1/2 spinor over the 6d3/2 spinor mean that excited states in nobelium atoms have 7s and 7p contribution instead of the expected 6d contribution. The long No–H distances in the NoH2 molecule and the significant charge transfer lead to extreme ionicity with a dipole moment of 5.94 D for this molecule. In this molecule, nobelium is expected to exhibit main-group-like behavior, specifically acting like an alkaline earth metal with its ns2 valence shell configuration and core-like 5f orbitals. Nobelium's complexing ability with chloride ions is most similar to that of barium, which complexes rather weakly. Its complexing ability with citrate, oxalate, and acetate in an aqueous solution of 0.5 M ammonium nitrate is between that of calcium and strontium, although it is somewhat closer to that of strontium. The standard reduction potential of the E°(No3+→No2+) couple was estimated in 1969 to be between +1.4 and +1.5 V; it was later found in 2009 to be only about +0.75 V.
Sources: en.wikipedia.org
The digital elevation model (DEM) is a raster-based digital dataset of the topography (hypsometry and/or bathymetry) of all or part of the Earth (or a telluric planet). The pixels of the dataset are each assigned an elevation value, and a header portion of the dataset defines the area of coverage, the units each pixel covers, and the units of elevation (and the zero-point). DEMs may be derived from existing paper maps and survey data, or they may be generated from new satellite or other remotely sensed radar or sonar data.
=== Electronation and de-electronation === The electrochemist John Bockris proposed the words electronation and de-electronation to describe reduction and oxidation processes, respectively, when they occur at electrodes. These words are analogous to protonation and deprotonation. IUPAC has recognized the terms electronation and de-electronation.
==== Agriculture ==== On 3 October 2021, the 53rd anniversary of Juan Velasco's rise to power via a military coup d'état, Castillo announced the start of the Second Agrarian Reform with the aim of helping small farmers and ending abuse and inequality. This was a tacit acknowledgement of the original Agrarian Reform carried out by Velasco. Castillo stated that the Second Agrarian Reform will respect property rights and will not involve the expropriation of land. However, Castillo also stated "Let's end with the bosses and the landowners. They will no longer eat thanks to the sweat of the poor and of the peasants." Castillo signaled that he would adjust the price bands to protect domestic agriculture from subsidized foreign products. Price bands for agriculture were created in 2001 for select goods, such as "hard yellow corn, milled rice, white sugar, and whole milk powder." However, over the years the price bands became increasingly liberalized, and by 2015 the price bands became nonexistent in practice. Castillo also spoke about his plan to industrialize coca leaf production and build an airport in Pichari so that goods can go directly to the national market. In a speech before a crowd, then Prime Minister Guido Bellido threatened Congress to approve the agrarian reform. "If Congress does not approve it, let the congressmen go and let the people choose other congressmen." Afterward, the attendees shouted: "Close the Congress!" Peru's Congress has been accused of obstructionism by supporters of the Castillo Administration.
== History == The first miP was discovered during a research in the early 1990s on genes for basic helix–loop–helix (bHLH) transcription factors from a murine erythroleukaemia cell cDNA library. The protein was an inhibitor of DNA binding (ID protein), and negatively regulated the transcription factor complex. The protein was 16 kDa and consisted of a helix-loop-helix (HLH) domain. The microprotein formed bHLH/HLH heterodimers that disrupted the functional basic helix–loop–helix (bHLH) homodimers. The first plant microprotein discovered was the LITTLE ZIPPER (ZPR) protein. The LITTLE ZIPPER protein contains a leucine zipper domain, but lacks the domains required for DNA binding and transcription activation. Thus, LITTLE ZIPPER protein is analogous to the ID protein. Although not all proteins are small, in 2011, this class of protein was given the name microproteins because their negative regulatory actions are similar to those of miRNAs. The ID protein or proteins similar to ID are found in all animals. Plant microproteins are only found in higher orders. However, the homeodomain transcription factors that belong to the three-amino-acid loop-extension (TALE) family are targets of microproteins, and these homeodomain proteins are conserved in animals, plants, and fungi.
Similar effects are known for related androgenic progestins like medroxyprogesterone acetate and megestrol acetate. CPA has also been reported to lower HDL cholesterol levels, another effect associated with androgens. Accordingly, CPA shows weak androgenic effects in the liver in rodents which can be blocked by flutamide.
Sources: en.wikipedia.org
=== Articles === Wadden, TA; Stunkard, AJ (1985). "The psychological and social consequences of obesity". Annals of Internal Medicine. 103 (6 ( Pt 2)): 1062–1067. doi:10.7326/0003-4819-103-6-1062. PMID 4062126. Wadden, TA; Bailey, TS; Billings, LK (2021). "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial". JAMA. 325 (14): 1403–1413. doi:10.1001/jama.2021.1831. PMC 7905697. PMID 33625476. Wadden, TA; Berkowitz, RI; Womble, LG (2005). "Randomized trial of lifestyle modification and pharmacotherapy for obesity". The New England Journal of Medicine. 353 (20): 2111–2120. doi:10.1056/NEJMoa050156. PMID 16291981. Wadden, TA; Webb, VL; Moran, CH; Bailer, BA (2012). "Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy". Circulation. 125 (9): 1157–1170. doi:10.1161/CIRCULATIONAHA.111.039453. PMC 3313649. PMID 22392863. Heymsfield, SB; Wadden, TA (2017). "Mechanisms, pathophysiology, and management of obesity". The New England Journal of Medicine. 376 (3): 254–266. doi:10.1056/NEJMra1514009. PMID 28099824. Wadden, Thomas A.; Tronieri, Jena S.; Butryn, Meghan L. (2020). "Lifestyle modification approaches for the treatment of obesity in adults". American Psychologist. 75 (2): 235–251. doi:10.1037/amp0000517. PMC 7027681. PMID 32052997.
=== Brush type columns (Pirkle Type) === The brush type, or Pirkle type chiral stationary phases are also called π-π Donnor-Acceptor columns. According to some theoretical models separation on these CSPs are based on a three-point attachment between the solute and the bonded chiral ligand on the surface of the stationary phase. These interactions may be attractive or repulsive in nature, depending on the mutual properties. Pirkle columns discriminate enantiomers by binding of one enantiomer with the chiral stationary phase, thereby forming a diastereomeric complex through π-π bonding, hydrogen bonding, steric interactions, and/or dipole stacking. Pirkle CSP can be categorized into three classes: (i) π-electron acceptor (ii) π-electron donor (iii) π-electron donor-π-electron acceptor.
To reduce radiation exposure, the American Society of Nuclear Cardiology (ASNC) issued dosage recommendations in 2010. The effective dose is 2.4 mSv for 13N-ammonia, 2.5 mSv for 15O-water, 7 mSv for 18F-fluorodeoxyglucose, and 13.5 mSv for 82Rb-rubidium chloride. Compliance with these recommendations is expected to reduce the average radiation exposure to = 9 mSv. The Ordinance on Radioactive Drugs or Drugs Treated with Ionizing Radiation § 2 AMRadV (in German) regulates the approval procedures for the marketability of radioactive drugs.
C1: methane only C2: ethane only C3: propane only C4: 2 isomers: n-butane and isobutane (i-butane) C5: 3 isomers: n-pentane, isopentane, and neopentane C6: 5 isomers: n-hexane, 2-methylpentane (isohexane), 3-methylpentane, 2,2-dimethylbutane (neohexane), and 2,3-dimethylbutane C7: 9 isomers: n-heptane, 2-methylhexane (isoheptane), 3-methylhexane, 2,2-dimethylpentane (neoheptane), 2,3-dimethylpentane, 2,4-dimethylpentane, 3,3-dimethylpentane, 3-ethylpentane, 2,2,3-trimethylbutane C8: 18 isomers: octane, 2-methylheptane, 3-methylheptane, 4-methylheptane, 2,2-dimethylhexane, 2,3-dimethylhexane, 2,4-dimethylhexane, 2,5-dimethylhexane, 3,3-dimethylhexane, 3,4-dimethylhexane, 3-ethylhexane, 2,2,3-trimethylpentane, 2,2,4-trimethylpentane, 2,3,3-trimethylpentane, 2,3,4-trimethylpentane, 3-ethyl-2-methylpentane, 3-ethyl-3-methylpentane, 2,2,3,3-tetramethylbutane C9: 35 isomers of nonane C10: 75 isomers of decane C11: 159 isomers of undecane C12: 355 isomers of dodecane C20: 366,319 isomers of eicosane (icosane) C30: 4,111,846,763 isomers of triacontane C40: 62,481,801,147,341 isomers of tetracontane C50: 1,117,743,651,746,953,270 isomers of pentacontane C60: 22,158,734,535,770,411,074,184 isomers of hexacontane Branched alkanes can be chiral. For example, 3-methylhexane and its higher homologues are chiral due to their stereogenic center at carbon atom number 3. The above list only includes differences of connectivity, not stereochemistry. In addition to the alkane isomers, the chain of carbon atoms may form one or more rings.
{\displaystyle {\frac {d}{dt}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}={\begin{pmatrix}-1/\tau _{E}&R_{0}/\tau _{I}\\1/\tau _{E}&-1/\tau _{I}\end{pmatrix}}{\begin{pmatrix}n_{E}\\n_{I}\end{pmatrix}}.}
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.